Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- 19 Jun 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2018.
- 19 Jun 2018 Status changed from not yet recruiting to recruiting.
- 11 Nov 2016 New trial record